Crizotinib for refractory vulvar malignant melanoma with equivocal MET amplification: a case report.
증례보고
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
pembrolizumab, nivolumab and brachytherapy for recurrence
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Next-generation sequencing may be suggested for refractory malignant melanoma. Crizotinib may be used to treat malignant melanoma with MET amplification.
[OBJECTIVE] Report the effect of crizotinib on one woman with refractory vulvar malignant melanoma and equivocal MET amplification.
APA
Liang CJ, Hsiao SM (2026). Crizotinib for refractory vulvar malignant melanoma with equivocal MET amplification: a case report.. Taiwanese journal of obstetrics & gynecology, 65(3), 600-601. https://doi.org/10.1016/j.tjog.2024.08.022
MLA
Liang CJ, et al.. "Crizotinib for refractory vulvar malignant melanoma with equivocal MET amplification: a case report.." Taiwanese journal of obstetrics & gynecology, vol. 65, no. 3, 2026, pp. 600-601.
PMID
42036199 ↗
Abstract 한글 요약
[OBJECTIVE] Report the effect of crizotinib on one woman with refractory vulvar malignant melanoma and equivocal MET amplification.
[CASE REPORT] One 62-year-old woman was diagnosed with vulvar malignant melanoma, AJCC stage IV, pT2aN0M1c. She received postoperative adjuvant therapy with 6 cycles of 75 mg/m of cisplatin and 200 mg/m of temozolomide, and then received pembrolizumab, nivolumab and brachytherapy for recurrence. However, she suffered multiple liver metastases and the recurrence was refractory to repeat pembrolizumab treatment. Next-generation sequencing examination revealed equivocal MET amplification. She received crizotinib (250 mg twice a day) based on the finding of equivocal MET amplification. Partial response was achieved based on the decreased size of liver metastases. However, liver metastasis deteriorated after 6 months of crizotinib. She died later despite salvage radiotherapy.
[CONCLUSION] Next-generation sequencing may be suggested for refractory malignant melanoma. Crizotinib may be used to treat malignant melanoma with MET amplification.
[CASE REPORT] One 62-year-old woman was diagnosed with vulvar malignant melanoma, AJCC stage IV, pT2aN0M1c. She received postoperative adjuvant therapy with 6 cycles of 75 mg/m of cisplatin and 200 mg/m of temozolomide, and then received pembrolizumab, nivolumab and brachytherapy for recurrence. However, she suffered multiple liver metastases and the recurrence was refractory to repeat pembrolizumab treatment. Next-generation sequencing examination revealed equivocal MET amplification. She received crizotinib (250 mg twice a day) based on the finding of equivocal MET amplification. Partial response was achieved based on the decreased size of liver metastases. However, liver metastasis deteriorated after 6 months of crizotinib. She died later despite salvage radiotherapy.
[CONCLUSION] Next-generation sequencing may be suggested for refractory malignant melanoma. Crizotinib may be used to treat malignant melanoma with MET amplification.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.